11 January 2019 - - US-based AgeX Therapeutics, Inc.'s (NYSE American: AGE) LifeMap Sciences, Inc subsidiary has partnered with Tianjin Novogene Medical Laboratory and Shanghai Shanyi to provide a combined, best-of-breed Clinical NGS analysis and interpretation platform for Tianjin Novogene Medical Laboratory's customers in China, the company said.

LifeMap Sciences' TGex is the provider of tertiary NGS analysis and interpretation solutions for rare pediatric disorders in the China market.

It is currently the clinical genetics solution of choice for top tier pediatric and maternal hospitals, including Peking Union Medical Center, Beijing Children's Hospital, Shanghai International Children's Medical Center, Shenzhen Maternal Hospital and Guanxi Maternal Hospital amongst others, as well as in private labs.

TGex is distributed in China by Shanghai Shanyi, which provides molecular technologies, services and solutions throughout the territory.

Novogene Tianjin Medical Laboratory is a CAP accredited clinical lab that provides high quality sequencing services to 1,920 scientific research institutes and universities, 720 hospitals, as well as 1,430 pharmaceutical and agricultural laboratories.

LifeMap Sciences is a life sciences technology company that offers integrated, streamlined solutions that empower life scientists worldwide to conduct cutting-edge basic, clinical and applied biomedical research.

The company's products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biopharma and diagnostic companies. Operations worldwide are carried out from our offices in California, Massachusetts, New Jersey, Tel Aviv, and Hong Kong. LifeMap is a subsidiary of AgeX Therapeutics, Inc.

Shanghai Shanyi is a provider of molecular technology service and solutions, including NGS interpretation, variant validation services, DNA Extraction solutions, dedicated in improving the molecular medical service quality in China.

AgeX Therapeutics is focused on developing and commercialising innovative therapeutics for human aging.

Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need.